Literature DB >> 30116971

Medically induced CSF rhinorrhea following treatment of macroprolactinoma: case series and literature review.

Tomáš Česák1, Pavel Poczos2,3, Jaroslav Adamkov1, Jiří Náhlovský1, Petra Kašparová4, Filip Gabalec5, Petr Čelakovský6, Ondrej Choutka7.   

Abstract

PURPOSE: Although several reports have addressed cerebrospinal fluid (CSF) rhinorrhea following dopamine agonist (DA) therapy of macroprolactinomas, further study is warranted for this relatively uncommon entity. Toward this aim, our retrospective series and review of literature further clarifies recommendations in treatment of this rare problem.
METHODS: We retrospectively reviewed all macroprolactinoma cases in our hospital for a 15-year period. Our systematic search of PubMed identified original articles and reviews of all macroprolactinoma cases with an associated medication-induced CSF leak.
RESULTS: Five patients with drug-induced CSF leak were identified; four of these patients received cabergoline therapy an average of 6 weeks before the onset of rhinorrhea and then underwent surgical repair of the CSF leak. Of 35 published studies included, we identified 60 patients with medication-induced CSF leak. Medical therapy included bromocriptine in 34 patients, cabergoline in 21 patients, and use of both DAs in two patients. Three cases did include complete diagnostic and treatment data. Median time from initiation of the DA treatment to occurrence of rhinorrhea was 6 weeks. For CSF rhinorrhea, 49 patients underwent surgical repair (38 by the transnasal approach) and seven patients were treated nonoperatively.
CONCLUSION: Baseline skull base erosion in macroprolactinomas in combination with subsequent tumor shrinkage induced by DA therapy may result in spontaneous CSF rhinorrhea. Therefore, such patients should be advised about and monitored for this potential setback. Once CSF leak is diagnosed, prompt treatment must be carried out to avoid infectious complications. Transnasal surgery appears the most effective therapeutic approach.

Entities:  

Keywords:  Cerebrospinal fluid leak; Dopamine agonists; Prolactinoma; Rhinorrhea

Mesh:

Substances:

Year:  2018        PMID: 30116971     DOI: 10.1007/s11102-018-0907-1

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  96 in total

1.  Cerebrospinal fluid pressure monitoring after repair of cerebrospinal fluid leaks.

Authors:  Rodney J Schlosser; Eileen Maloney Wilensky; M Sean Grady; James N Palmer; David W Kennedy; William E Bolger
Journal:  Otolaryngol Head Neck Surg       Date:  2004-04       Impact factor: 3.497

2.  Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role.

Authors:  K Vleminckx; L Vakaet; M Mareel; W Fiers; F van Roy
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

Review 3.  Diagnosis of cerebrospinal fluid rhinorrhea: an evidence-based review with recommendations.

Authors:  Gretchen M Oakley; Jeremiah A Alt; Rodney J Schlosser; Richard J Harvey; Richard R Orlandi
Journal:  Int Forum Allergy Rhinol       Date:  2015-09-15       Impact factor: 3.858

4.  A novel reconstructive technique after endoscopic expanded endonasal approaches: vascular pedicle nasoseptal flap.

Authors:  Gustavo Hadad; Luis Bassagasteguy; Ricardo L Carrau; Juan C Mataza; Amin Kassam; Carl H Snyderman; Arlan Mintz
Journal:  Laryngoscope       Date:  2006-10       Impact factor: 3.325

5.  Role of matrix metalloproteinase 9 in pituitary tumor behavior.

Authors:  H E Turner; Z Nagy; M M Esiri; A L Harris; J A Wass
Journal:  J Clin Endocrinol Metab       Date:  2000-08       Impact factor: 5.958

6.  Giant invasive prolactinomas.

Authors:  F Y Murphy; D L Vesely; R M Jordan; S Flanigan; P O Kohler
Journal:  Am J Med       Date:  1987-11       Impact factor: 4.965

7.  Age-related and gender-related occurrence of pituitary adenomas.

Authors:  T Mindermann; C B Wilson
Journal:  Clin Endocrinol (Oxf)       Date:  1994-09       Impact factor: 3.478

8.  Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.

Authors:  A Colao; A Di Sarno; M L Landi; S Cirillo; F Sarnacchiaro; G Facciolli; R Pivonello; M Cataldi; B Merola; L Annunziato; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

Review 9.  Update on prolactinomas. Part 2: Treatment and management strategies.

Authors:  Anni Wong; Jean Anderson Eloy; William T Couldwell; James K Liu
Journal:  J Clin Neurosci       Date:  2015-08-01       Impact factor: 1.961

10.  Management of macroprolactinomas.

Authors:  Amit Tirosh; Ilan Shimon
Journal:  Clin Diabetes Endocrinol       Date:  2015-07-20
View more
  3 in total

1.  SPONTANEOUS CEREBROSPINAL FLUID LEAK AFTER INITIATION OF DOPAMINE AGONIST THERAPY IN MACROPROLACTINOMAS: TWO CASE REPORTS AND A LITERATURE REVIEW.

Authors:  Jonea Lim; Mitali Talsania; Madona Azar
Journal:  AACE Clin Case Rep       Date:  2020-03-04

2.  Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors.

Authors:  Renato Cozzi; Maria Rosaria Ambrosio; Roberto Attanasio; Claudia Battista; Alessandro Bozzao; Marco Caputo; Enrica Ciccarelli; Laura De Marinis; Ernesto De Menis; Marco Faustini Fustini; Franco Grimaldi; Andrea Lania; Giovanni Lasio; Francesco Logoluso; Marco Losa; Pietro Maffei; Davide Milani; Maurizio Poggi; Michele Zini; Laurence Katznelson; Anton Luger; Catalina Poiana
Journal:  Eur J Endocrinol       Date:  2022-02-03       Impact factor: 6.664

Review 3.  Update in Pathogenesis, Diagnosis, and Therapy of Prolactinoma.

Authors:  Noriaki Fukuhara; Mitsuru Nishiyama; Yasumasa Iwasaki
Journal:  Cancers (Basel)       Date:  2022-07-24       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.